Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…
PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR
PROVISION Study, Prospective Randomized Trial Evaluating Clinical Outcomes of FFRangio Versus FFR…
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
May 10, 2025 10:00 ET | Source: Akero Therapeutics Inc. Analysis of…
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) today announced that GPCR Therapeutics…
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq:…
OMNICOM MEDIA GROUP AGENCY OMD TAKES TOP SLOT IN RECMA DIAGNOSTICS REPORT FOR NINTH CONSECUTIVE EDITION, REINFORCING ITS LEAD IN THE MARKETPLACE
NEW YORK, March 20, 2025 /PRNewswire/ -- In the latest edition of…
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
- Full data from the Phase 3 TRuE-PN1 study, presented today in…
Best’s Review Explores How Carriers Are Strengthening Relationships With Independent Agents
OLDWICK, N.J.--(BUSINESS WIRE)--The March issue of Best’s Review examines the relationship between…
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
February 08, 2025 14:30 ET | Source: 4D Molecular Therapeutics, Inc. 3E10…